BIODESIX INC (BDSX)

Company Profile

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 245 full-time employees. The company went IPO on 2020-10-28. Biodesix is focused on using technologies with its artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs in lung disease. Biodesix is providing diagnostic testing services associated with blood-based lung tests; coronavirus disease tests and providing biopharmaceutical companies with services that include diagnostic research, clinical research, development, and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Its blood-based lung cancer tests include Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. Biodesix also offers SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralizing Antibody testing.

Company Info

BIODESIX INC

Suite 100, 2970 Wilderness Place

Boulder COLORADO

P: 13034170500

Employees: 245

Website: https://www.biodesix.com/